The acquisition expands Veracyte's bladder cancer franchise with a differentiated urine-based platform, but the first product launch is not expected until late 2028, limiting near-term revenue impact. Monitor for integration updates and any changes to 2026 guidance in upcoming 10-Q filings.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Sep 15 $40.14entry
- T+1 · 2mo ago −4.09%α −3.64% · $38.50
- T+5 · 8w ago +8.02%α +5.89% · $43.36
- T+20 · 5w ago +7.40%α +4.68% · $43.11
- T+44 · todayOpen
- T+60 · in 22d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Veracyte acquires Convergent Genomics for $150M upfront plus up to $30M in milestone payments, adding the UroAmp urinary tumor DNA platform for bladder cancer monitoring. The deal strengthens Veracyte's bladder cancer portfolio across urine, tissue, and blood, with the first UroAmp test expected to commercialize in late 2028. The acquisition is funded from cash and Veracyte is not updating its 2026 adjusted EBITDA guidance.
Key Financial Metrics
Key Facts
- Veracyte acquires Convergent Genomics for $150M upfront cash plus up to $30M in milestone payments tied to UroAmp reimbursement.
- UroAmp is a urine-based tumor DNA platform validated in non-muscle invasive bladder cancer (NMIBC) for therapy-response monitoring and surveillance.
- First UroAmp test expected to commercialize in late 2028, subject to reimbursement timelines.
- Veracyte is not updating its previously provided 2026 adjusted EBITDA guidance to reflect the acquisition.
- UroAmp is supported by nine peer-reviewed publications and over 40 posters/abstracts.
- In the RUMBLE study, utDNA-positive patients had 25% 12-month recurrence-free survival vs. 91% for utDNA-negative patients.
Financial Impact
$150M upfront cash plus up to $30M milestone payments; Veracyte not updating 2026 EBITDA guidance.
Risk Factors
- Integration risk and potential delays in UroAmp commercialization timeline.
- Reimbursement uncertainty for the first UroAmp test could affect milestone payments and revenue ramp.
- Competing liquid biopsy and urine-based tests may emerge in the NMIBC monitoring space.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3361535 |
Track record
22 reports on VCYT
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +20.37% at T+20 after the Jun 11, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $24.63 Now $24.01 −2.52% settles Dec 11
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $24.00 Now $24.01 +0.04% settles Dec 4
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $24.00 Now $24.01 +0.04% settles Dec 4
- Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $50.01 Now $24.01 −51.99% settles Nov 30
- Oct 28, 202619d ago Insider Cluster Neutral 2/10 Entry $52.17 Now $24.01 −53.98% settles Nov 27
- Oct 28, 202619d ago Insider Cluster Neutral 3/10 Entry $52.17 Now $24.01 −53.98% settles Nov 27
- Oct 27, 202620d ago 144 Neutral 2/10 Entry $50.31 Now $24.01 −52.28% settles Nov 25
- Oct 27, 202620d ago 144 Neutral 2/10 Entry $50.31 Now $24.01 −52.28% settles Nov 25
- Sep 22, 20267w ago Insider Cluster Neutral 2/10 Entry $43.82 to $46.22 Now $24.01 −45.21% ▲ +5.48% +4.79% vs SPY
- Sep 14, 20269w ago Press Release Bullish 6/10 Viewing Entry $40.14 to $43.11 Now $24.01 −40.18% ▲ +7.40% +4.68% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers